vs

Side-by-side financial comparison of Ultragenyx Pharmaceutical Inc. (RARE) and Rubrik, Inc. (RBRK). Click either name above to swap in a different company.

Rubrik, Inc. is the larger business by last-quarter revenue ($350.2M vs $207.3M, roughly 1.7× Ultragenyx Pharmaceutical Inc.). Rubrik, Inc. runs the higher net margin — -18.2% vs -62.0%, a 43.8% gap on every dollar of revenue. On growth, Rubrik, Inc. posted the faster year-over-year revenue change (48.3% vs 25.9%). Rubrik, Inc. produced more free cash flow last quarter ($80.7M vs $-100.8M).

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Rubrik, Inc. is an American cloud data management and data security company based in Palo Alto, California, founded in January 2014. The company is listed on the New York Stock Exchange after going public in April 2024.

RARE vs RBRK — Head-to-Head

Bigger by revenue
RBRK
RBRK
1.7× larger
RBRK
$350.2M
$207.3M
RARE
Growing faster (revenue YoY)
RBRK
RBRK
+22.4% gap
RBRK
48.3%
25.9%
RARE
Higher net margin
RBRK
RBRK
43.8% more per $
RBRK
-18.2%
-62.0%
RARE
More free cash flow
RBRK
RBRK
$181.5M more FCF
RBRK
$80.7M
$-100.8M
RARE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
RARE
RARE
RBRK
RBRK
Revenue
$207.3M
$350.2M
Net Profit
$-128.6M
$-63.8M
Gross Margin
80.5%
Operating Margin
-54.7%
-21.6%
Net Margin
-62.0%
-18.2%
Revenue YoY
25.9%
48.3%
Net Profit YoY
3.5%
51.2%
EPS (diluted)
$-1.28
$-0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RARE
RARE
RBRK
RBRK
Q4 25
$207.3M
$350.2M
Q3 25
$159.9M
$309.9M
Q2 25
$166.5M
$278.5M
Q1 25
$139.3M
$258.1M
Q4 24
$164.6M
$236.2M
Q3 24
$139.5M
$205.0M
Q2 24
$147.0M
$187.3M
Q1 24
$108.8M
Net Profit
RARE
RARE
RBRK
RBRK
Q4 25
$-128.6M
$-63.8M
Q3 25
$-180.4M
$-95.9M
Q2 25
$-115.0M
$-102.1M
Q1 25
$-151.1M
$-114.9M
Q4 24
$-133.2M
$-130.9M
Q3 24
$-133.5M
$-176.9M
Q2 24
$-131.6M
$-732.1M
Q1 24
$-170.7M
Gross Margin
RARE
RARE
RBRK
RBRK
Q4 25
80.5%
Q3 25
79.5%
Q2 25
78.3%
Q1 25
77.4%
Q4 24
76.2%
Q3 24
73.1%
Q2 24
48.8%
Q1 24
Operating Margin
RARE
RARE
RBRK
RBRK
Q4 25
-54.7%
-21.6%
Q3 25
-106.9%
-30.5%
Q2 25
-64.8%
-33.4%
Q1 25
-102.6%
-45.0%
Q4 24
-74.3%
-52.8%
Q3 24
-94.6%
-82.1%
Q2 24
-79.1%
-387.0%
Q1 24
-151.9%
Net Margin
RARE
RARE
RBRK
RBRK
Q4 25
-62.0%
-18.2%
Q3 25
-112.8%
-31.0%
Q2 25
-69.0%
-36.7%
Q1 25
-108.5%
-44.5%
Q4 24
-80.9%
-55.4%
Q3 24
-95.7%
-86.3%
Q2 24
-89.5%
-390.8%
Q1 24
-156.8%
EPS (diluted)
RARE
RARE
RBRK
RBRK
Q4 25
$-1.28
$-0.32
Q3 25
$-1.81
$-0.49
Q2 25
$-1.17
$-0.53
Q1 25
$-1.57
$5.69
Q4 24
$-1.34
$-0.71
Q3 24
$-1.40
$-0.98
Q2 24
$-1.52
$-11.48
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RARE
RARE
RBRK
RBRK
Cash + ST InvestmentsLiquidity on hand
$421.0M
$307.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-80.0M
$-524.4M
Total Assets
$1.5B
$2.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RARE
RARE
RBRK
RBRK
Q4 25
$421.0M
$307.1M
Q3 25
$202.5M
$322.7M
Q2 25
$176.3M
$284.0M
Q1 25
$127.1M
$186.3M
Q4 24
$174.0M
$103.9M
Q3 24
$150.6M
$142.3M
Q2 24
$480.7M
$502.6M
Q1 24
$112.3M
Stockholders' Equity
RARE
RARE
RBRK
RBRK
Q4 25
$-80.0M
$-524.4M
Q3 25
$9.2M
$-564.3M
Q2 25
$151.3M
$-556.5M
Q1 25
$144.2M
$-553.7M
Q4 24
$255.0M
$-521.1M
Q3 24
$346.8M
$-499.3M
Q2 24
$432.4M
$-514.6M
Q1 24
$140.3M
Total Assets
RARE
RARE
RBRK
RBRK
Q4 25
$1.5B
$2.5B
Q3 25
$1.2B
$2.4B
Q2 25
$1.3B
$1.5B
Q1 25
$1.3B
$1.4B
Q4 24
$1.5B
$1.3B
Q3 24
$1.5B
$1.2B
Q2 24
$1.6B
$1.2B
Q1 24
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RARE
RARE
RBRK
RBRK
Operating Cash FlowLast quarter
$-99.8M
$85.5M
Free Cash FlowOCF − Capex
$-100.8M
$80.7M
FCF MarginFCF / Revenue
-48.6%
23.1%
Capex IntensityCapex / Revenue
0.5%
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M
$256.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RARE
RARE
RBRK
RBRK
Q4 25
$-99.8M
$85.5M
Q3 25
$-91.4M
$64.7M
Q2 25
$-108.3M
$39.7M
Q1 25
$-166.5M
$83.6M
Q4 24
$-79.3M
$23.1M
Q3 24
$-67.0M
$-27.1M
Q2 24
$-77.0M
$-31.4M
Q1 24
$-190.7M
Free Cash Flow
RARE
RARE
RBRK
RBRK
Q4 25
$-100.8M
$80.7M
Q3 25
$-92.7M
$61.2M
Q2 25
$-110.7M
$36.8M
Q1 25
$-167.8M
$78.0M
Q4 24
$-79.5M
$18.0M
Q3 24
$-68.6M
$-29.7M
Q2 24
$-79.0M
$-35.0M
Q1 24
$-193.9M
FCF Margin
RARE
RARE
RBRK
RBRK
Q4 25
-48.6%
23.1%
Q3 25
-58.0%
19.8%
Q2 25
-66.5%
13.2%
Q1 25
-120.5%
30.2%
Q4 24
-48.3%
7.6%
Q3 24
-49.2%
-14.5%
Q2 24
-53.7%
-18.7%
Q1 24
-178.2%
Capex Intensity
RARE
RARE
RBRK
RBRK
Q4 25
0.5%
1.4%
Q3 25
0.8%
1.1%
Q2 25
1.5%
1.0%
Q1 25
1.0%
2.2%
Q4 24
0.1%
2.1%
Q3 24
1.2%
1.3%
Q2 24
1.4%
1.9%
Q1 24
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

RBRK
RBRK

Subscription And Circulation$336.4M96%
Other$12.3M4%
Software And Services$4.9M1%
Maintenance$1.5M0%

Related Comparisons